Controversies in the Management of Gynecological CancersJonathan A. Ledermann, Carien L. Creutzberg, Michael A. Quinn Springer Science & Business Media, 13 gru 2013 - 349 This is a novel text that highlights the controversial areas in the management of gynecological cancers. None of the topics in this book have definitive answers; they represent the everyday decision-making facing gynecologists, oncologists, radiologists, pathologists and other health professionals treating women with these conditions. This book is not to be used as a traditional textbook; it is a text that specialists and trainees will use to help them weigh up the arguments that exist in a variety of areas in the treatment of gynecological cancers. Each chapter will have two or more authors, selected either for their opposing views or for their ability to provide an opposite view or opinion to the other. The content will be evidence-based, illustrating contrasting evidence and scientific opinion in the literature. Each chapter will close on a summary indicating the direction of research needed to address the issues being discussed. |
Spis treści
| 1 | |
| 16 | |
New Views of Ovarian Carcinoma Types How Will This Change Practice? | 29 |
Lymphadenectomy in Endometrial Cancer The Controversy Rages Unabated | 39 |
What Is the Role of Adjuvant Radiotherapy and Chemotherapy in Endometrial Cancer? | 47 |
Chemotherapy andor Targeted Therapies for Advanced Endometrial Cancer Time to Rethink? | 58 |
Is Cervix Cancer a Disappearing Disease? Impact of HPV Vaccination in Developed Countries | 69 |
What Is the Role of Cytotoxic Chemotherapy in Advanced Cervical Cancer? | 79 |
Sentinel Node BiopsyDoes It Help in the Management of Vulvar Cancer? | 175 |
Controversies in the Management of Advanced Vulvar Cancer | 184 |
Bowel Obstruction in Ovarian Cancer To Operate or Not? | 197 |
Early Cervical Cancer Can Fertility Be Safely Preserved? | 203 |
What Is the Role of PETCT in Gynecological Cancers? | 213 |
Do IntensityModulated Radiation ImageGuided Radiation and 3D Brachytherapy Significantly Advance Radiotherapeutic Management of Gynecolo... | 224 |
What Is the Place of Hormone Replacement Therapy in Ovarian Endometrial and Breast Cancer? | 237 |
Familial Gynecologic Cancers Whom to Screen and How to Manage? | 247 |
Response as a Measure of Treatment Efficacy in Clinical Trials Should RECIST Be Abandoned? | 91 |
What Are the Treatment Options for Recurrent Ovarian Cancer? | 101 |
How to Study Rare Gynecological Tumors Trials or Registries? | 111 |
What Is the Best Treatment Model for Gynecologic Cancers? Does Centralization Help? | 120 |
When Should Surgery Be Performed for the FirstLine Treatment of Advanced Ovarian Cancer? | 135 |
Does Intraperitoneal Therapy for Ovarian Cancer Have a Future? | 144 |
Maintenance Therapy for FirstLine Treatment of Ovarian Cancer Is This the Strategy for the Future? | 155 |
What Is the Value of Lymphadenectomy in Early Ovarian Cancer? | 164 |
Trial Design Should Randomized Phase III Trials in Gynecological Cancers Be Abandoned? | 262 |
How Should Early Gestational Trophoblastic Disease Be Managed? | 285 |
Should Every Woman with Gynecologic Cancer Undergo Routine Screening for Psychological Distress and Sexual Dysfunction? | 297 |
How Should Gynecological Sarcomas Be Managed? | 309 |
What Is the Future of Immunotherapy in Ovarian Cancer? | 322 |
| 339 | |
Inne wydania - Wyświetl wszystko
Kluczowe wyrazy i wyrażenia
adjuvant chemotherapy advanced ovarian cancer assessment benefit bevacizumab biopsy bowel obstruction breast cancer carboplatin cervical cancer chemo cisplatin clear cell Clin Oncol clinical trials debulking detection diagnosis disease dose doxorubicin early-stage effect endometrial cancer endometrial carcinoma epithelial ovarian cancer Epub estrogen evaluation follow-up groin Gynecol Oncol gynecologic cancer Gynecologic Oncology Group high-risk hormone hysterectomy impact improved Int J Gynecol lymphadenectomy malignant median metastasis metastatic mutation neoadjuvant chemotherapy ObstetGynecol oncologists Oncology Group study optimal outcome ovarian carcinoma overall survival paclitaxel para-aortic patients with advanced pelvic peritoneal PET/CT phase III trial primary PubMed PMID Radiat Oncol Biol radical radiotherapy randomized phase randomized trials receptor RECIST recurrent ovarian cancer regimen relapse resection response rate risk sarcoma screening sentinel lymph node sentinel node serous carcinoma target tion toxicity trachelectomy treated treatment trophoblastic tumor uterine uterine sarcomas vaccination vaginal versus vulvar cancer women